With more than 2,000 drugs reintroduced for alternative purposes to date, drug repositioning has become a viable solution for pharmaceutical companies to generate additional revenue. The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, provided deeper insight today into the unique approach its Life Sciences consulting service takes in analyzing drugs and drug candidates to identify those with potential for repositioning.
Are non-U.S. online pharmacies safe to use? The U.S. Food and Drug Administration would like you to think they are not, but independent research continues to show that they are. New data published by the National Bureau of Economic Research (NBER) found that medication ordered from credentialed online pharmacies, foreign or domestic, was genuine and safe. Only non-credentialed pharmacies sold products which were not genuine. The main difference between credentialed foreign and domestic pharmacies was price: Non-U.S. pharmacies sold the same drugs at an average 51% discount.
Agilent Technologies Inc. today announced that it has entered into a comarketing agreement with Molecular Discovery Ltd. to provide biopharmaceutical researchers with an advanced metabolite-identification platform. The companies will comarket the combined assets of Agilent's high-resolution liquid chromatography/mass spectrometry (LC/MS) technology and Molecular Discovery's Mass-MetaSite software to enable superior identification and analysis of complex biological mixtures.
Omeros Corp. announced that it has identified compounds that functionally interact with each of five additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 42 Class A orphan GPCRs, representing over half of these targets. There are approximately 120 orphan GPCRs and Omeros expects to unlock a large percentage of them, focusing first on Class A orphans.
Most people who have diabetes, high blood pressure, and high cholesterol have difficultly managing all three conditions; indeed, success is fleeting for those who do manage all three, according to a Kaiser Permanente Institute for Health Research study that appears online in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.
BioClinica Inc., a global provider of clinical trial management solutions, announced that it is, together with C.R. Bard, a 2012 winner of Microsoft Corporation’s prestigious Life Sciences Innovation Award. The awards, announced at the Drug Information Association’s (DIA) 48th Annual Meeting in Philadelphia, honor companies that use Microsoft solutions to realize business and information technology benefits.
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a collaboration agreement with a top-5 pharmaceutical company to extend and enhance its oral cavity dosing model within its industry gold standard GastroPlus™ simulation software program.
Battelle, a global leader in health care research and development, unveiled a unique and innovative collaboration model that will enhance the efficiency of the pharmaceutical industry's drug discovery efforts.
New research shows a sharp escalation in the weapons race against cancer, with several high-tech approaches long dreamed of but not possible or successful until now.
At a weekend conference of more than 30,000 cancer specialists, scientists reported:
—New "smart" drugs that deliver powerful poisons directly to cancer cells while leaving healthy ones alone.
—A new tool that helps the immune system attack a broad range of cancer types.
Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy